BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22554523)

  • 1. Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.
    Oh B; Park S; Pak JH; Kim I
    Biochem Biophys Res Commun; 2012 May; 422(1):42-7. PubMed ID: 22554523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
    Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
    Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
    Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
    Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
    Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
    Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein.
    Han Y; Park S; Kinyua AW; Andera L; Kim KW; Kim I
    Oncol Rep; 2014 Jan; 31(1):456-62. PubMed ID: 24213797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents.
    Sánchez-Pérez T; Ortiz-Ferrón G; López-Rivas A
    Cell Death Differ; 2010 May; 17(5):883-94. PubMed ID: 19942932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G; Zhan Y; Wang H; Li W
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-κB.
    Guo SY; Liu SG; Liu L; Zhou XJ; Gu Y
    Oncol Rep; 2012 Feb; 27(2):441-6. PubMed ID: 22020406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins.
    Lee SJ; Noh HJ; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
    Int J Oncol; 2011 Feb; 38(2):485-92. PubMed ID: 21170508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax.
    Park SJ; Park SH; Kim JO; Kim JH; Park SJ; Hwang JJ; Jin DH; Jeong SY; Lee SJ; Kim JC; Kim I; Cho DH
    Biochem Biophys Res Commun; 2012 Nov; 428(1):185-90. PubMed ID: 23068102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
    Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
    Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X; Li H
    Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
    Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
    Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.